Quote: "The pharmacists and the insurance do not have to waste their time to separate indication..."
The only distinction they need to make is whether the drug is the generic or the brand...And the brand in this case will be cheaper because it is indicated for the CVD indication and has no cheaper molecule for that indication and therefore will have a low tier price..
The courts have declared generics can not claim the R-I indication because the infringes on Amarin' patents..So the only indication the Generics can claim is the Marine high trigs..(regardless if they really intend to use it for the CVD indication)...That puts them in exactly the same position Amarin's Vascepa faced the past two years..That is with only the Marine label they faced competition from drugs like Lovaza which are cheaper molecules Which also lower trigs... Last year all our complaints about the out of pocket costs for Vascepa was due to the fact the only FDA label we had was for the Marine high trigs...and since Lovaza was a cheaper molecule the Insurance companies put Vascepa at a high tier...This time Amarin has no legal cheaper competition for the R-I label...and that means lower Tier levels..There is no violation of insurance dictum of supporting the cheapest molecule..
News 
Market Data 
Discover 
AI
